CODX Key Statistics, Chart & Performance
The current stock price of CODX is 0.3745 USD. In the past month the price decreased by -4.97%. In the past year, price decreased by -55.99%.
CODX Latest News, Press Relases and Analysis
CODX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.07 | 217.50B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.82 | 203.96B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.06 | 144.57B | ||
| SYK | STRYKER CORP | 27.64 | 139.21B | ||
| IDXX | IDEXX LABORATORIES INC | 56.63 | 57.02B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.59B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.54 | 50.02B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.62 | 38.93B | ||
| RMD | RESMED INC | 25.91 | 37.45B | ||
| DXCM | DEXCOM INC | 35.21 | 25.54B | ||
| PODD | INSULET CORP | 66.63 | 21.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.65 | 18.68B |
Related stock screener links
About CODX
Company Profile
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Company Info
CO-DIAGNOSTICS INC
2401 S. Foothill Dr. Suite D
Salt Lake City UTAH 84109 US
CEO: Dwight Egan
Employees: 132
Phone: 18014381036
CO-DIAGNOSTICS INC / CODX FAQ
What does CO-DIAGNOSTICS INC do?
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Can you provide the latest stock price for CO-DIAGNOSTICS INC?
The current stock price of CODX is 0.3745 USD. The price decreased by -3.1% in the last trading session.
Does CO-DIAGNOSTICS INC pay dividends?
CODX does not pay a dividend.
What is the ChartMill rating of CO-DIAGNOSTICS INC stock?
CODX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is CO-DIAGNOSTICS INC (CODX) stock traded?
CODX stock is listed on the Nasdaq exchange.
Can you provide the market cap for CO-DIAGNOSTICS INC?
CO-DIAGNOSTICS INC (CODX) has a market capitalization of 22.80M USD. This makes CODX a Nano Cap stock.
CODX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CODX. When comparing the yearly performance of all stocks, CODX is a bad performer in the overall market: 83.17% of all stocks are doing better.
CODX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CODX. CODX has a great financial health rating, but its profitability evaluates not so good.
CODX Financial Highlights
Over the last trailing twelve months CODX reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 22.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.93% | ||
| ROE | -80.8% | ||
| Debt/Equity | 0 |
CODX Forecast & Estimates
8 analysts have analysed CODX and the average price target is 2.04 USD. This implies a price increase of 444.73% is expected in the next year compared to the current price of 0.3745.
For the next year, analysts expect an EPS growth of 33.65% and a revenue growth -87.61% for CODX